BioAge Labs (BIOA) EBT Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly EBT Margin came in at 1056.55% in Q2 2026, down 16302.0% year-over-year from N/an in Q2 2025, and down 32.25% quarter-over-quarter from 798.92% in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) EBT Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed EBT Margin across 2 years of filings, most recently posting 1056.55% for Q2 2026.
- In Q2 2026, EBT Margin fell 16302.0% year-over-year to 1056.55%; the TTM figure through Jun 2026 stood at 906.75% (up 114414.0% YoY), while the FY2025 annual figure was 893.73%, changed N/A from the prior year.
- EBT Margin came in at 1056.55% for Q2 2026 at BioAge Labs, down from 798.92% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 798.92% in Q1 2026 to a low of 1056.55% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | -1,056.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,056.55% |
| Mar 31, 2026 | -798.92% |
| Dec 31, 2025 | -835.71% |
| Sep 30, 2025 | -979.99% |
| Jun 30, 2025 | -893.53% |
| Mar 31, 2025 | -895.04% |